Mark Lakshmanan

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial

Katherine R. Tuttle, Mark Lakshmanan, Brian Rayner et al. · The Lancet Diabetes & Endocrinology · 2018 · 608 citations

Metabolic Syndrome, Diabetes Management, Renal Function +9

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 600 citations · Full text

Metabolic Syndrome, Diabetes Management, Urology +10

Teriparatide for acceleration of fracture repair in humans: A prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures

Per Aspenberg, Harry K. Genant, Torsten Johansson et al. · Journal of Bone and Mineral Research · 2009 · 504 citations · Full text

Skeletal Trauma, Animal Experiments, Bone Disease +14

Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)

Carol Wysham, Thomas Blevins, Richard F. Arakaki et al. · Diabetes Care · 2014 · 371 citations